Skip to main content
Premium Trial:

Request an Annual Quote

Moderna Seeks Approval

Moderna is seeking full approval from the US Food and Drug Administration for its mRNA-based SARS-CoV-2 vaccine, CNBC reports.

The company received emergency use authorization from the regulatory agency for its vaccine in December, which allowed people over the age of 18 in the US to receive the shot. As CNBC notes, approval requires additional data and would enable Moderna to market the vaccine directly to consumers.

"We are pleased to announce this important step in the US regulatory process for a Biologics License Application of our COVID-19 vaccine," Stéphane Bancel, CEO of Moderna, says in a statement. "We look forward to working with the FDA and will continue to submit data from our Phase 3 study and complete the rolling submission."

CNBC notes that the FDA approval process may take months.

Moderna is the second SARS-CoV-2 vaccine maker to announce its intention to seek FDA approval. In May, Pfizer and BioNTech said they would be seeking approval for their vaccine.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.